Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein Therapeutic for Topical Treatment of Dry Eye Disease
5/8/2013 1:56:42 PM
More...
|
Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting
4/24/2013 11:42:34 AM
More...
|
Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease
2/19/2013 9:43:09 AM
More...
|
Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically-delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease
12/10/2012 9:58:48 AM
More...
|
Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease
5/8/2012 10:17:14 AM
More...
|
Eleven Biotherapeutics Rakes in $20 Million Fundraise
5/8/2012 6:32:44 AM
More...
|
Eleven Biotherapeutics to Present at the Association for Research in Vision & Ophthalmology 2012 Annual Meeting
4/24/2012 10:35:57 AM
More...
|
Eleven Biotherapeutics Taps Abbie Celniker, Ph.D. as New CEO
9/22/2011 6:50:46 AM
More...
|
Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development
1/6/2011 8:58:35 AM
More...
|
Eleven Biotherapeutics Receives Three Federal Grants to Develop Innovative Protein-Based
11/5/2010 10:47:58 AM
More...
|
|